Trade Summary

2 days ago, Sloan Sheldon, serving as Chief Medical Officer at Spyre Therapeutics, Inc. (SYRE), sold 8,333 shares at $75.00 per share, for a total transaction value of $624,975.00.

This sale represents a 100.00% decrease in Sloan Sheldon's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, June 3, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, June 4, 2026 (accepted Jun 3, 9:32 PM ET), 1 day after the trade was made.

Spyre Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.